About Nephros, Inc.
Nephros, Inc. became a Delaware corporation on April 3, 1997
Nephros is a company committed to improving the human relationship with water through leading, accessible technology. We provide innovative filtration and pathogen detection as part of an integrated approach to water safety that combines science, solutions, and support services. Nephros products serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency responses for water management.
As a 2019 and 2020 Deloitte “Fast 500” biotechnology company (2019 and 2020) publicly traded on the Nasdaq (Nasdaq: NEPH), we continuously demonstrate consistently high revenue growth and product innovation. Our leading water filtration and testing science, education, and outstanding customer support represent a comprehensive, integrated approach to water safety. While we are most known for our FDA-cleared infection control water filters, we acquired Aether Water Systems to deliver more complete and integrated turnkey solutions to our customers. Our commitment to enhanced engineering, research and development, and quality control position our filtration technology to be arguably the gold standard.
We excel at identifying and retaining harmful contaminants; and bringing awareness to the risks, regulatory guidance, and opportunities for improvement as they pertain to water quality. To bolster our pathogen detection capabilities, we acquired GenArraytion, Inc., a manufacturer of infectious disease monitoring and measurement products. This acquisition bolstered our ability to detect and mitigate the spread of infectious disease, while empowering customers to conduct on-site water testing quickly and accurately.
NASDAQ Stock Symbol: NEPH
380 Lackawanna Place
South Orange, NJ 07079
For help transferring a share certificate into a trust or another name, replacing a lost share certification, or to setup online deliveries of shareholder materials:
Looking for more information?
Meet the Nephros Board of Directors, responsible for assessing the overall direction and strategy for how we improve the human relationship with water.
Tom is currently Chief Information Officer (CIO) at the London Stock Exchange. Prior positions have included CIO and Chief Technology…
Alisa brings more than 20 years of commercial experience in sales and marketing across pharmaceutical, medical device, and cosmeceutical sectors….
Oliver is currently the Chief Financial Officer, Executive Vice President and a member of the board of directors of IDOC,…
Arthur is a partner of Wexford Capital and serves as its General Counsel. He actively participates in various private equity…